Shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $22.60.
A number of analysts recently issued reports on the company. StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Thursday, February 27th. Jefferies Financial Group initiated coverage on Wave Life Sciences in a report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 target price for the company. Mizuho increased their price target on Wave Life Sciences from $19.00 to $22.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Truist Financial lifted their price objective on Wave Life Sciences from $17.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, November 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday.
Check Out Our Latest Analysis on Wave Life Sciences
Institutional Trading of Wave Life Sciences
A number of institutional investors have recently modified their holdings of WVE. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Wave Life Sciences during the fourth quarter valued at approximately $4,482,000. Polar Asset Management Partners Inc. boosted its holdings in Wave Life Sciences by 14.7% in the fourth quarter. Polar Asset Management Partners Inc. now owns 557,323 shares of the company's stock worth $6,894,000 after acquiring an additional 71,300 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Wave Life Sciences during the fourth quarter valued at about $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Wave Life Sciences by 14.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,238 shares of the company's stock valued at $2,044,000 after purchasing an additional 20,520 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in shares of Wave Life Sciences in the fourth quarter worth $10,463,000. 89.73% of the stock is currently owned by institutional investors.
Wave Life Sciences Price Performance
Shares of NASDAQ:WVE traded down $0.39 on Monday, hitting $10.18. 1,084,043 shares of the company's stock were exchanged, compared to its average volume of 920,313. The business's 50 day simple moving average is $11.51 and its two-hundred day simple moving average is $11.18. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -9.17 and a beta of -1.09. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74.
Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.34. The company had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. Equities analysts forecast that Wave Life Sciences will post -1.14 EPS for the current fiscal year.
About Wave Life Sciences
(
Get Free ReportWave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Recommended Stories
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
